Researcher armed with the expertise of staff seasoned in the ways of the drug industry, unveiled his blueprint to address sky-high drug prices Friday afternoon, promising that increasing industry competition will help Americans save at the pharmacy counter.

"Under this administration, we are putting American patients first," Trump said  with Secretary of Health and Human Services Alex Azar by his side. Azar, he said, had a mission to "to bring soaring drug prices down to Earth." Trump said he plans to work with Congress on lowering drug costs. The administration is planning or considering 50 actions to reduce what Americans pay for drugs, including giving Medicare more power to negotiate drug prices, Azar said.

Trump called the plan "the most sweeping action in history to lower the price of prescription drugs to the American people." They will have tougher negotiations, more competition and much lower prices at the pharmacy counters. And it will start to take effect very soon. Trump's proposals target reducing the out-of-pocket costs for older Americans enrolled in Medicare — but experts say that amounts to more show than substance.

"There's a difference between reducing the pain people feel associated with out-of-pocket costs at the pharmacy counter and reducing the actual national spend on prescription drugs," said Allan Coukell, senior director for health programs at the nonpartisan Pew Charitable Trusts. While 80% of Americans say the cost of drugs is unreasonable, 1 in 4 people reports having difficulty paying for drugs, according to Kaiser Family Foundation polling. 

Some policy experts said Trump's announcement includes mostly old ideas.Trump's plan includes tackling the rising costs of drugs in Medicare's Part B program, which pays for drugs delivered in doctor's offices or hospital outpatient setting a challenge previous administrations have failed to tackle.

While the details are still vague, Trump has called for the prices paid for certain drugs under Part B these could include expensive drugs for cancer chemotherapy and rheumatoid arthritis to be negotiated using the same tactics insurers and pharmacy benefit managers use under Medicare Part D, which is the program that seniors use for their retail prescription drugs.